{"entity":{"id":"nct06041802","kind":"trial","name":"A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)","aka":[],"tldr":"A phase 2 trial of Pembrolizumab in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39) is a phase 2 interventional study registered as NCT06041802 by Merck Sharp & Dohme LLC, with 19 participants enrolled, started 2023-10-20 and due to reach its primary completion in 2028-03-31. Interventions recorded: Pembrolizumab (+) Berahyaluronidase alfa.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06041802","url":"https://clinicaltrials.gov/study/NCT06041802"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06041802","phase":"2","setting":"A Phase 2 Clinical Study to Evaluate the Safety and Efficacy of MK-3475A in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC.","sponsor":"Merck Sharp & Dohme LLC","enrolled":19,"outcomes":[]},"route":"/trials/nct06041802/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}